Positive update on SFX-01 in vitro GBM studies
19/02/2024 11:22
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240219:nRSS6330Da&default-theme=true
RNS Number : 6330D Evgen Pharma PLC 19 February 2024
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Positive update on SFX-01 in vitro Glioblastoma (GBM) studies
Further evidence of SFX-01 activity as seen at other academic centres
Alderley Park, UK - 19 February 2024: Evgen Pharma plc (AIM: EVG), the
clinical stage drug development company developing sulforaphane-based
medicines for the treatment of multiple diseases, announces that the
laboratory of Dr Marjolein Geurts, neuro-oncologist at the Erasmus University
Medical Centre has observed continuing activity of SFX-01 in GBM cells.
The in vitro studies, which are supported by a grant awarded by the KWF Dutch
Cancer Society for a €1.1m project, are designed to investigate the activity
of SFX-01 in preclinical GBM models. This work is to be followed by
administration of SFX-01 to patients with GBM in a clinical Investigator
Sponsored Study (ISS). The scientific collaboration, which commenced in
October 2023, will run for three years, generating data continuously
throughout the period.
According to the lead investigator, Dr Marjolein Geurts, neuro-oncologist at
Erasmus University Medical Center, "We have seen continued evidence of
biological activity in patient-derived glioblastoma tissue."
Dr Huw Jones, CEO of Evgen Pharma said:
"These early data triangulate with those seen by our other academic
collaborators in Abbruzzo, Italy and Auckland, New Zealand. This is another
major academic group observing these effects in tissue derived from a
different population of GBM patients which gives us further confidence of
SFX-01's potential as a therapeutic option for glioblastoma, a disease with
very high unmet medical needs which is devastating for patients and their
carers."
-Ends-
Enquiries
Evgen Pharma plc +44 207 457 2020
Dr Huw Jones, CEO enquiries@evgen.com
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish Capital Markets (NOMAD and Broker) +44 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
Instinctif Partners +44 207 457 2020
Evgen@Instinctif.com
Melanie Toyne-Sewell / Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing
sulforaphane based medicines for the treatment of multiple diseases. The
Company's core technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane and novel
proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b
study of the Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be
investigated initially in this indication as an investigator sponsored study
in the Netherlands.
The Company also has a wide number of collaborations with leading academic
centres in the UK, Europe and the US as part of the continuing strategy to
build the scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum disorder. The
deal, if successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com (http://www.evgen.com)
.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAQKCBBDBKDKBD